ARRIVENT BIOPHARMA INC (AVBP) Stock Income Statement
NASDAQ:AVBP - Nasdaq - US04272N1028 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 140.41M | 94.31M | 74.59M | 36.91M | 8.70M | |||
| Research and Development | 123.32M | 79.00M | 64.88M | 30.43M | 6.43M | |||
| Selling, General, and Administrative Expenses | 17.09M | 15.30M | 9.71M | 6.47M | 2.26M | |||
| Operating Income | -140.41M | -94.31M | -74.59M | -36.91M | -8.70M | |||
| Interest Income/Expense | 12.95M | 13.82M | 5.26M | N/A | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | 0.00 | -42.91M | |||
| Income Before Taxes | -127.46M | -80.49M | -69.33M | -36.91M | -51.61M | |||
| Net Income | -127.46M | -80.49M | -69.33M | -36.91M | -51.61M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.78 | -2.56 | -2.17 | -1.15 | -1.61 | |||
| Non GAAP EPS | -3.77 | -2.57 | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD